

in the corporate respondent such as dissolution, assignment or sale resulting in the emergence of a successor corporation, the creation or dissolution of subsidiaries or any other change in the corporation which may affect compliance with obligations arising out of the order.

IN THE MATTER OF

STERLING DRUG INC.

ORDER, OPINION, ETC., IN REGARD TO THE ALLEGED VIOLATION OF
SEC. 7 OF THE CLAYTON ACT

Docket 8797. Complaint, Aug. 7, 1969—Decision, April 7, 1972.

Order modifying and adopting hearing examiner's decision dismissing complaint that a New York City drug firm selling a broad range of health and beauty aid products violated Section 7 of the Clayton Act in acquiring another New York City company manufacturing and selling health and beauty aids, household deodorizer and other non-food consumer products.

COMPLAINT

The Federal Trade Commission has reason to believe that Sterling Drug Inc., a corporation and the respondent herein, has merged with Lehn & Fink Products Corporation, a corporation, in violation of Section 7 of the Clayton Act, as amended (15 U.S.C. 18); therefore, pursuant to Section 11 of the Clayton Act, as amended (15 U.S.C. 21), it issues this Complaint, stating its charges in that respect as follows:

I Definitions

1. For purposes of this complaint, the following definitions are applicable:

(a) Proprietary Drugs—pharmaceutical preparations advertised to the public;

(b) Personal Care Products—perfumes, cosmetics, and other toilet preparations advertised to the public;

(c) Health and Beauty Aids—All products which are either proprietary drugs or personal care products, as defined above;

(d) Household Aerosol Deodorizers—products in aerosol form which are designed to purify air in the household by removing odors or destroying germs; and

(e) Nonfood Household Consumer Products—chemically-based products which are advertised to the public and used in the house-

STERLING DRUG, INC.

477

471

Complaint

in the corporate respondent such as dissolution, assignment or sale